



Company Overview

Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases.

Immune Pharmaceuticals Engages Extera Partners to Pursue Bertilimumab Strategic Transaction

December 18 2018, 8:30 AM EST

Immune Pharmaceuticals Announces Adjournment of Special Meeting of Stockholders

December 6 2018, 9:00 AM EST

Immune Pharmaceuticals and Vector Therapeutics Sign Option Agreement for Worldwide Ceplene® Rights

November 27 2018, 7:30 AM EST

Stock Overview

Symbol	IMNP
Exchange	OTCQB
Market Cap	719.98k
Last Price	\$0.0146
52-Week	\$0.0028 - \$0.66

01/16/2019 03:59 PM EST

Investor Relations

Investors@immunepharma.com

Management Team

Tony Fiorino, MD, PhD

Interim Chief Executive Officer

John Zhang, MD, PhD

Vice President, Research and Development

Immune Pharmaceuticals, Inc.

1 Bridge Plaza N
Suite 270
Fort Lee, NJ 07024

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.